Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer contested...

    Bayer contested Glyphosate use will eventually end, says German Chancellor

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-28T09:15:01+05:30  |  Updated On 28 Jun 2019 9:15 AM IST
    Bayer contested Glyphosate use will eventually end, says German Chancellor

    Bayer, which has been struggling to outrun the glyphosate crisis, two weeks ago announced it would spend 5 billion euros in researching alternative pesticides, but said it believed the weedkiller had a future.


    BERLIN: Use of Bayer's contested weedkiller glyphosate, the subject of more than 10,000 lawsuits in the U.S. over claims it causes cancer, will eventually die out, German Chancellor Angela Merkel told the country's lower house on Wednesday.


    Merkel's view is seemingly at odds with that of Bayer, which acquired the pesticide along with its takeover of U.S. seed maker Monsanto, which earlier this month said it saw a future for the product.


    Read Also: Bayer Stivarga becomes first drug to be tested in brain cancer patients in multi-arm cooperation trial


    Bayer's shares hit seven-year lows after a California couple was last month awarded more than $2 billion in the largest-ever U.S. jury award over claims that glyphosate-based weedkiller Roundup, caused their cancer.


    "Things are developing, and we will eventually come to a point where glyphosate isn't deployed any more," she told lawmakers, adding that this should be achieved without overburdening farmers.


    Bayer, which has been struggling to outrun the glyphosate crisis, two weeks ago announced it would spend 5 billion euros in researching alternative pesticides, but said it believed the weedkiller had a future.


    "While glyphosate will continue to play an important role in agriculture and in Bayer's portfolio, the company is committed to offering more choices for growers," Bayer said at the time.


    Read Also: Bayer to invest $5.6 billion in weedkilling research


    Glyphosate-based herbicides, in use for more than 40 years, are the most commonly applied weed control products in the world.


    Direct glyphosate sales play only a minor role for Bayer's earnings because various other crop chemical companies supply the off-patent herbicide, but seeds to grow glyphosate-resistant crops are a key profit driver in North and South America.


    Bayer has maintained that glyphosate is safe and has pointed to global regulators' findings that its use is safe.


    Read Also: Bayer arm liable for farmer sickness over weedkiller

    Angela MerkelBayercancerglyphosateMonsantounited satesweedweedkillerweedkiller glyphosate
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok